The smoke from the Pap wars is beginning to clear. Of the three companies with FDA-cleared approaches to cervical cancer screening, Cytyc Corp. 's gamble seems to be paying off best. NeoPath Inc. continues to fit into the "promising but not quite certain" category and the prognosis for Neuromedical Systems Inc. is poor. Two developments this month indicated just how far the situation has come.
First, Cytyc and Dianon Systems Inc. , an anatomic pathology laboratory (see"Consolidation in Diagnostics: AmeriPath vs. Dianon," IN VIVO,...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?